HIV and hepatitis C virus infection in the United States: Whom and how to test

Clinical Infectious Diseases

Volumn 59, Issue 6, 2014, Pages 875-882

  Panneer, Nivedha ^a   Lontok, Erik ^a   Branson, Bernard M ^b   Teo, Chong Gee ^b   Dan, Corinna ^c   Parker, Monica ^d   Stekler, Joanne D ^e,f   DeMaria Jr , Alfred ^g   Miller, Veronica ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^c U S DEPARTMENT OF HEALTH AND HUMAN SERVICES   (United States)

^d WADSWORTH CENTER   (United States)

^e UNIVERSITY OF WASHINGTON   (United States)

^f PUBLIC HEALTH SEATTLE AND KING COUNTY   (United States)

^g MASSACHUSETTS DEPARTMENT OF PUBLIC HEALTH   (United States)

Author keywords

HCV; Hepatitis C virus; HIV; Nucleic acid test; Testing algorithm

Indexed keywords

NUCLEIC ACID;

ARTICLE; DISEASE CONTROL; HEPATITIS C; HEPATITIS C VIRUS; HIV TEST; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; NUCLEIC ACID ANALYSIS; PREVENTIVE HEALTH SERVICE; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; UNITED STATES; FEMALE; FOOD AND DRUG ADMINISTRATION; HEPACIVIRUS; HIV INFECTIONS; LEGISLATION AND JURISPRUDENCE; MALE; MASS SCREENING; PHYSIOLOGY; PROCEDURES; PUBLIC HEALTH SERVICE; STANDARDS;

CENTERS FOR DISEASE CONTROL AND PREVENTION (U.S.); FEMALE; HEPACIVIRUS; HEPATITIS C; HIV; HIV INFECTIONS; HUMANS; MALE; MASS SCREENING; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 84907401006     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/ciu396     Document Type: Article

References (40)

1. Centers for Disease Control and Prevention. Monitoring selected national HIV prevention and care objectives by using HIV surveillance data - United States and 6 U.S. dependent areas - 2011. HIV Surveillance Supplemental Report 2013; 18 (No. 5). Available at: http://www.cdc.gov/hiv/pdf/2011-Monitoring-HIV- Indicators-HSSR-FINAL.pdf. Accessed 25 March 2014.
2. Centers for Disease Control and Prevention. Estimated HIV incidence in the United States, 2007-2010, HIV Surveillance Supplemental Report 2012; 17 (No. 4). Available at: http://www.cdc.gov/hiv/topics/surveillance/resources/reports/ #supplemental. Accessed 25 March 2014.
3. Denniston MM, Jiles RB, Drobenius J, et al. Chronic hepatitis C virus infection in the United States, National Health and Nutrition Examination Survey 2003 to 2010. Ann Intern Med 2014; 160:293-300.
4. Centers for Disease Control and Prevention. Recommendations for the identification of chronic hepatitis C virus infection among persons born during 1945-1965. MMWR Recomm Rep 2012; 61:1-32.
5. Douek DC, Roederer M, Koup RA. Emerging concepts in the immunopathogenesis of AIDS. Annu Rev Med 2009; 60:471-84.
6. Bartenschlager R, Lohmann V. Replication of hepatitis C virus. J Gen Virol 2000; 81(pt 7):1631-48.
7. van de Laar T, Pybus O, Bruisten S, et al. Evidence of a large, international network of HCV transmission in HIV-positive men who have sex with men. Gastroenterology 2009; 136:1609-17.
8. Alter MJ. Prevention of spread of hepatitis C. Hepatology 2002; 36(5 suppl 1):S93-8.
9. Collaboration of Observational HIV Epidemiological Research Europe (COHERE) in EuroCoord. All-cause mortality in treated HIV-infected adults with CD4 >/=500/mm3 compared with the general population: evidence from a large European observational cohort collaboration. Int J Epidemiol 2012; 41:433-45.
10. Wada N, Jacobson LP, Cohen M, French A, Phair J, Munoz A. Cause-specific mortality among HIV-infected individuals, by CD4(+) cell count at HAART initiation, compared with HIV-uninfected individuals. AIDS 2014; 28:257-65.
11. McHutchison JG, Lawitz EJ, Shiffman ML, et al. Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection. N Engl J Med 2009; 361:580-93.
12. Sulkowski MS, Gardiner DF, Rodriguez-Torres M, et al. Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection. N Engl J Med 2014; 370:211-21.
13. Younossi ZM, Stepanova M, Afendy M, Lam BP, Mishra A. Knowledge about infection is the only predictor of treatment in patients with chronic hepatitis C. J Viral Hepat 2013; 20:550-5.
14. Patient Protection and Affordable Care Act. Public Law No: 111-148 Sec 2713.
15. White House Office of National AIDS Policy. National HIV/AIDS strategy for the United States. Available at: http://aids.gov/federal-resources/national- hiv-aids-strategy/nhas.pdf. Accessed 1 July 2012.
16. Department of Health and Human Services. Combating the silent epidemic of viral hepatitis: action plan for the prevention, care and treatment of viral hepatitis, updated 2014-2016. Available at: http://aids.gov/pdf/viral-hepatitis- action-plan.pdf. Accessed 3 April 2014.
17. Centers for Disease Control and Prevention. Revised recommendations for HIV testing of adults, adolescents, and pregnant women in healthcare settings. MMWR Recomm Rep 2006; 55:1-17.
18. US Preventive Services Task Force. Screening for HIV. Available at: http://www.uspreventiveservicestaskforce.org/uspstf/uspshivi.htm. Accessed 30 April 2013.
19. Cohen MS, Chen YQ, McCauley M, et al. Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med 2011; 365:493-505.
20. Centers for Disease Control and Prevention. Recommendations for prevention and control of hepatitis C virus (HCV) infection and HCV-related chronic disease. MMWR Recomm Rep 1998; 47:1-39.
21. US Preventive Services Task Force. Screening for hepatitis C virus infection in adults. Available at: http://www.uspreventiveservicestaskforce.org/ uspstf/uspshepc.htm. Accessed 1 August 2013.
22. American Association for the Study of Liver Disease. Recommendations for testing, managing, and treating hepatitis C. Available at: http://www. hcvguidelines.org/. Accessed 3 April 2014.
23. Clinical and Laboratory Standards Institute. M53-A criteria for laboratory testing and diagnosis of human immunodeficiency virus infection; approved guideline. Wayne, PA; CLSI, 2011; 31.
24. Centers for Disease Control and Prevention and Association of Public Health Laboratories. Laboratory Testing for the Diagnosis of HIV Infection: Updated Recommendations. Available at: http://stacks.cdc.gov/view/cdc/23447. Published June 27, 2014. Accessed 2 July 2014.
25. Bennett B, Neumann D, Fordan S, Villaraza R, Crowe S, Gillis L. Performance of the new HIV-1/2 diagnostic algorithm in Florida's public health testing population: a review of the first five months of utilization. J Clin Virol 2013; 58(suppl 1):e29-33.
26. Ramos EM, Harb S, Dragavon J, Senson P, Stekler JD, Coombs RW. Performance of an alternative HIV diagnostic algorithm using the ARCHITECT HIV Ag/Ab Combo assay and potential utility of sample-to-cutoff ratio to discriminate primary from established infection. J Clin Virol 2013; 58(suppl 1):e38-43.
27. Centers for Disease Control and Prevention. Revised surveillance case definition for HIV infection - United States, 2014. MMWR Recomm Rep 2014; 63:1-10.
28. Centers for Disease Control and Prevention. Testing for HCV infection: an update of guidance for clinicians and laboratorians. MMWR Morb Mortal Wkly Rep 2013; 62:362-5.
29. Maasoumy B, Bemer B, Manns MP, Cornberg M, Wedemeyer H. Storage conditions of plasma samples do not significantly influence reported HCV RNA results in a low viremic setting. In: 64th Annual Meeting of American Association for the Study of Liver Diseases, 4 November 2013, Washington, DC.
30. Shaw S, Cresswell F, Homer G, Hassan-Ibrahim M, Fisher M. Hepatitis C antigen testing: a reliable alternative for diagnosing acute HCV infection. In: 21st Conference On Retroviruses and Opportunistic Infections, 5 March 2014, Boston, MA.
31. Zitzer H, Heilek G, Truchon K, et al. Second-generation Cobas AmpliPrep/Cobas TaqMan HCV quantitative test for viral load monitoring: a novel dual-probe assay design. J Clin Microbiol 2013; 51:571-7.
32. Scott L, Carmona S, Stevens W. Performance of the new Roche Cobas AmpliPrep-Cobas TaqMan version 2.0 human immunodeficiency virus type 1 assay. J Clin Microbiol 2009; 47:3400-2.
33. Clinical Laboratory Improvement Amendments. Interpretive guidelines for laboratories and laboratory service; subpart K - quality system for nonwaived testing D5423 §493.1253 standard: establishment and verification of performance specifications. Available at: http://www.cms.gov/Regulations-and- Guidance/Legislation/CLIA/Downloads/apcsubk1.pdf. Accessed 3 April 2014.
34. Burd EM. Validation of laboratory-developed molecular assays for infectious diseases. Clin Microbiol Rev 2010; 23:550-76.
35. Aberg JA, Gallant JE, Ghanem KG, Emmanuel P, Zingman BS, Horberg MA. Primary care guidelines for the management of persons infected with HIV: 2013 update by the HIV Medicine Association of the Infectious Diseases Society of America. Clin Infect Dis 2014; 58:1-10.
36. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. Available at: http://aidsinfo.nih.gov/ contentfiles/lvguidelines/adultandadolescentgl.pdf. Accessed 1 August 2013.
37. Muir AJ. The rapid evolution of treatment strategies for hepatitis C. Am J Gastroenterol 2014; 109:628-35.
38. Backus LI, Boothroyd DB, Phillips BR, Belperio P, Halloran J, Mole LA. A sustained virologic response reduces risk of all-cause mortality in patients with hepatitis C. Clin Gastroenterol Hepatol 2011; 9:509-16.e1.
39. Reau NS, Jensen DM. Sticker shock and the price of new therapies for hepatitis C: is it worth it? Hepatology 2014; 59:246-1249.
40. Martin NK, Vickerman P, Grebely J, et al. Hepatitis C virus treatment for prevention among people who inject drugs: modeling treatment scale-up in the age of direct-acting antivirals. Hepatology 2013; 58:1598-609.